Literature DB >> 18412283

PET study of brain acetylcholinesterase in cerebellar degenerative disorders.

Shigeki Hirano1, Hitoshi Shinotoh, Kimihito Arai, Akiyo Aotsuka, Fumihiko Yasuno, Noriko Tanaka, Tsuneyoshi Ota, Koichi Sato, Kiyoshi Fukushi, Shuji Tanada, Takamichi Hattori, Toshiaki Irie.   

Abstract

To elucidate characteristic changes of brain acetylcholinesterase (AChE) in cerebellar degenerative disorders. Eight patients with the cerebellar variant of multiple system atrophy (MSA-C), 7 patients with spinocerebellar ataxia type-3 (SCA-3), 3 patients with SCA-6, and 13 healthy age-matched volunteers participated in this study. Brain AChE activity was measured by [(11)C] N-methylpiperidin-4-yl propionate PET in all subjects. Brain AChE activities were significantly decreased in the thalamus (-27%) and the posterior lobe of cerebellar cortex (-36%) in patients with MSA-C and in the thalamus (-23%) in patients with SCA-3 compared with healthy controls (P < 0.01). Thalamic AChE activities of SCA-3 patients were negatively correlated with the unified Parkinson's disease rating scale motor subscore (P < 0.001). AChE activities were not significantly altered in the cerebral cortex in any disease group. Reduction of AChE activities in the thalamus and cerebellum in MSA and in the thalamus in SCA-3 suggest that cholinergic modulating drugs may have a role in the treatment of ataxia and other symptoms in these disorders. (c) 2008 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18412283     DOI: 10.1002/mds.22056

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes.

Authors:  S Gilman; R A Koeppe; B Nan; C-N Wang; X Wang; L Junck; R D Chervin; F Consens; A Bhaumik
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 2.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

Review 3.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

4.  Gating of long-term potentiation by nicotinic acetylcholine receptors at the cerebellum input stage.

Authors:  Francesca Prestori; Claudia Bonardi; Lisa Mapelli; Paola Lombardo; Rianne Goselink; Maria Egle De Stefano; Daniela Gandolfi; Jonathan Mapelli; Daniel Bertrand; Martijn Schonewille; Chris De Zeeuw; Egidio D'Angelo
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

5.  [(123)I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: A specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6).

Authors:  Joachim Mazere; Wassilios G Meissner; Igor Sibon; Frédéric Lamare; François Tison; Michèle Allard; Willy Mayo
Journal:  Neuroimage Clin       Date:  2013-08-08       Impact factor: 4.881

6.  Different subregional metabolism patterns in patients with cerebellar ataxia by 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Minyoung Oh; Jae Seung Kim; Jungsu S Oh; Chong Sik Lee; Sun Ju Chung
Journal:  PLoS One       Date:  2017-03-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.